Published in:
01-02-2004 | Poster presentation
Development of a comprehensive new endpoint for the evaluation of new treatments for acute decompensated heart failure: results with levosimendan in the REVIVE 1 study
Authors:
C Garratt, M Packer, W Colucci, L Fisher, B Massie, J Teerlink, J Young
Published in:
Critical Care
|
Special Issue 1/2004
Login to get access
Excerpt
Traditionally, intravenous (IV) drugs in decompensated heart failure (HF) have been evaluated based on their hemodynamic effects. Thus, no endpoint to measure symptomatic improvement in decompensated HF has yet been validated. To do so, we adapted the clinical composite (which has been validated in trials of chronic HF) to the evaluation of IV levosimendan in a pilot trial of acute decompensated HF (REVIVE-1). …